BioCentury
ARTICLE | Deals

Bristol Myers adds CV therapy through $13.1B MyoKardia takeout

With MyoKardia deal, BMS doubles its CV pipeline, diversifies beyond cancer

October 5, 2020 5:24 PM UTC

BMS is looking to diversify beyond its heavy reliance on its cancer portfolio through a $13.1 billion takeout of cardiovascular company MyoKardia.

For MyoKardia Inc. (NASDAQ:MYOK), the $225 per share acquisition price is a 61% premium to Friday’s close of $139.60. The biotech’s shares had reached a 52-week high of $140.93 during Friday’s session...

BCIQ Company Profiles

MyoKardia Inc.